MedTrace Logo

EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients

NCT00963248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2015-04-13

No results posted yet for this study

Summary

Question:

In which stage of an EBV-infection is a selective reduction of immunosuppressive medication reasonable to minimize the risk for PTLD, without putting the transplant recipient at risk of acute rejection episodes due to under immunosuppression?

Aim of study:

Identification of patients at high-risk for PTLD.

Conditions

  • Epstein-Barr Virus Infections

Sponsors & Collaborators

  • Klinik für Kinder- und Jugendmedizin

    lead OTHER

Principal Investigators

  • Burkhard Toenshoff, MD, PhD · University Children's Hospital of Heidelberg

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963248 on ClinicalTrials.gov